SimonMed Advances Outpatient Lung Imaging Through Partnership with 4DMedical

New FDA-cleared technologies expand access to functional and quantitative lung analysis at SimonMed locations nationwide, helping physicians better evaluate respiratory symptoms and lung disease.

SimonMed, one of the nation's largest outpatient diagnostic imaging and health technology providers, today announced the clinical launch of two advanced lung imaging technologies, CT:VQ™ and LDAf™, in partnership with global medical technology company 4DMedical. Available at SimonMed locations nationwide, the technologies expand access to functional and quantitative lung analysis, helping physicians gain a more comprehensive understanding of lung health beyond what conventional CT imaging alone can reveal.

As 4DMedical's first outpatient imaging-group partner, SimonMed is bringing these advanced capabilities into community-based imaging settings, reinforcing its commitment to making innovative medical technologies more widely accessible to physicians and the patients they serve.

The announcement coincides with November's COPD Awareness Month, highlighting the importance of improving the evaluation of respiratory conditions. For patients experiencing persistent shortness of breath, chronic cough or other unexplained respiratory symptoms, identifying the underlying cause can be challenging. These technologies provide additional information to support clinical assessment and care decisions.

"Shortness of breath is a common symptom, but understanding its underlying cause isn't always straightforward," said Dr. Sean Raj, Chief Medical Officer and Chief Innovation Officer at SimonMed. "These technologies add functional and quantitative insights to chest CT, helping physicians look beyond structure for a more detailed picture of lung health to support the evaluation of conditions such as COPD, emphysema and asthma."

Both FDA-cleared technologies use specialized software to analyze non-contrast chest CT imaging, providing complementary insights into lung health.

• CT:VQ™ maps ventilation and perfusion to show how air and blood flow through different regions of the lungs. Traditionally assessed through nuclear medicine scans, these functions can now be evaluated using CT-without injected contrast, radioactive tracers or specialized nuclear medicine equipment.
• LDAf™ quantifies low-density lung tissue and air trapping to support the evaluation of obstructive lung disease.

Physicians can order either analysis individually or together to support evaluation of patients with persistent respiratory symptoms, abnormal pulmonary function tests, or known or suspected lung disease.

"At SimonMed, our goal is to make the most advanced imaging technologies accessible to more people, helping physicians make informed decisions and patients better understand their health," said Dr. John Simon, Founder and CEO of SimonMed. "Our partnership with 4DMedical is another example of how we're bringing meaningful innovation into outpatient care."

"Bringing the newest, breakthrough lung imaging tools to the marketplace requires partners with vision and technical prowess," declares Dr. Andreas Fouras, Founder and CEO of 4DMedical. "SimonMed is exactly the right care provider to bring 4D's advanced CT:VQ® and LDAf™ to its outpatient imaging network. That gives physicians new and ready access to detailed, functional and quantitative lung insights for patients-and simultaneously extends 4D technology further into the U.S. market."

CT:VQ™ and LDAf™ are available by physician order at SimonMed locations nationwide. Insurance coverage varies by plan, and applicable copays, coinsurance and deductibles may apply.

About SimonMed

Headquartered in Scottsdale, Arizona, SimonMed is one of the largest outpatient diagnostic imaging and health technology providers in the United States. SimonMed operates more than 180 centers across 10 states and is supported by a nationwide team of more than 300 subspecialty-trained, board-certified radiologists. SimonMed provides the full spectrum of diagnostic imaging services from X-ray to complex Cardiac MRI and is a recognized leader in the clinical use of artificial intelligence.

SimonMed Longevity is a division focused on proactive health. It offers whole-body MRI and preventive, multi-modality screening designed to help patients establish a baseline of their health, track changes over time, and identify potential risk earlier-when informed action may help prevent or delay disease.

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that is revolutionizing respiratory care with advanced imaging and artificial intelligence. 4DMedical's patented technologies transform standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease. 4DMedical's portfolio includes the FDA-cleared, ground-breaking CT:VQ^® solution designed to set new benchmarks in functional lung imaging with combined ventilation and perfusion analysis from standard non-contrast CT scans.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of Imbio and 2026 acquisition of contextflow, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.